SCHEMBL21180073

SCHEMBL21180073

O=Cc1c(O)ccc2[nH]c(C(O)O)cc12

nearest known ligand 0.44

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 17/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14925523 0.74 KDM4E (0.50) ERN1
SCHEMBL2563604 0.71 ERN1 (0.55) ERN1
SCHEMBL28321998 0.68 ERN1 (0.61) ERN1
SCHEMBL31236213 0.68 ERN1 (0.61) ERN1
SCHEMBL7471060 0.67 KDM4E (0.52) ERN1
SCHEMBL2567378 0.67 ALOX15 (0.47) ERN1
SCHEMBL29111409 0.65 ERN1 (0.56) ERN1
SCHEMBL14916137 0.65 HRH4 (0.66)
SCHEMBL14916494 0.65 ERN1 (0.55) ERN1
SCHEMBL7682570 0.65 ERN1 (0.47) ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10357475-B2 IRE-1α inhibitors FOSUN ORINOVE PHARMATECH, INC. (CN) 2019-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10357475-B2 IRE-1α inhibitors XBP1, ERN1, ERN2 ERN1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.